Drug Delivery Systems

Lipid nanoparticles transformed RNA medicine during the pandemic and now anchor an expanding pipeline of mRNA, siRNA, and CRISPR therapeutics including Casgevy, the first approved CRISPR-Cas9 product. The track will cover next-generation LNPs with tissue tropism beyond the liver, GalNAc-conjugated siRNA durability (inclisiran, vutrisiran, zilebesiran), and the engineering breakthroughs enabling oral peptides such as semaglutide and orforglipron. Sessions will also address microneedle patches, intratumoral and intrathecal delivery, AAV capsid engineering for in-vivo gene therapy, and the emerging non-viral platforms targeting hematopoietic stem cells in situ.